What is Zai Lab?
Founded in 2014 and headquartered in Shanghai, Zai Lab operates as a high-growth bio-pharmaceutical enterprise dedicated to addressing significant unmet medical needs. The company leverages a sophisticated drug discovery platform to identify and develop innovative therapies, focusing primarily on oncology, autoimmune diseases, and infectious diseases. By bridging the gap between global innovation and the Chinese market, Zai Lab has established itself as a critical player in the international life sciences ecosystem, effectively managing a diverse portfolio of clinical-stage assets and commercialized products.
How much funding has Zai Lab raised?
Zai Lab has raised a total of $1.4B across 6 funding rounds:
Series A
$30M
Series B
$100M
Series C
$30M
Stock Offering
$150M
Share Placement
$261.3M
Stock Offering
$825M
Series A (2014): $30M with participation from TF Capital, Steamboat Ventures, Qiming Venture Partners, and Kleiner Perkins
Series B (2016): $100M led by OrbiMed, Qiming Venture Partners, TF Capital, Steamboat Ventures, and Advantech Capital
Series C (2017): $30M supported by Vivo Capital, Rock Springs Capital, OrbiMed, and Cormorant Asset Management
Stock Issuance/Offering (2017): $150M, investors not publicly disclosed
Share Placement (2020): $261.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $825M, investors not publicly disclosed
Key Investors in Zai Lab
OrbiMed
OrbiMed is a specialized healthcare investment firm with deep expertise across biopharmaceuticals and medical devices, managing capital to support companies from early-stage ventures to established organizations.
Kleiner Perkins
Kleiner Perkins is a prominent venture capital firm that provides both capital and operational support to early and growth-stage technology and life science companies.
Cormorant Asset Management
Cormorant Asset Management is a life sciences-focused investment firm that utilizes fundamental scientific principles to back innovative private and public biotech companies.
What's next for Zai Lab?
Looking ahead, Zai Lab is positioned to leverage its recent capital infusion to scale its research and development capabilities and strengthen its market presence. The company's strategic roadmap likely involves the expansion of its late-stage clinical trials and the potential acquisition of additional high-potential therapeutic assets. As the firm transitions into a more mature phase of its lifecycle, the focus will remain on operational excellence, regulatory navigation, and the successful commercialization of its pipeline, ensuring long-term value creation for stakeholders in the competitive global healthcare market.
See full Zai Lab company page
